Clinical Trials Logo

Filter by:
NCT ID: NCT06289803 Recruiting - Pancreatic Cancer Clinical Trials

The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Aim of the study: To evaluate the value of Probe Confocal Laser Endomicroscopy (PCLE) in surgery for pancreatic tumor. Methods: Patients who are diagnosed with pancreatic tumor based on preoperative radiographic findings and will undergo radical resection are included in this clinical study. PCLE will be used in surgery to identify tumor is malignant or not, and surgeons will decide procedures of surgery based on outcomes of PCLE. In this present study, clinical trials will be divided into two phases. In the first phase, based on the definitive postoperative pathologic diagnosis, characteristic imaging structures that were collected by PCLE will be identified and primary diagnostic imaging criteria for pancreatic cancer would be developed. In the second phase, this criterion will be used for rapid intraoperative diagnosis of pancreatic cancer and predicting status of resection margin. In addition, accuracy of PCLE will be verified based on postoperative pathologic reports.

NCT ID: NCT06289751 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.

NCT ID: NCT06289530 Recruiting - Clinical trials for Postoperative Pancreatic Fistula

Association Between Perioperative Blood and Interstitial Fluid Glucose Level and Clinically Relevant Postoperative Pancreatic Fistula in Different Pancreatic Surgeries

CR-POPF
Start date: March 1, 2024
Phase:
Study type: Observational

This observational study was conducted in patients undergoing elective pancreaticoduodenectomy or distal pancreatectomy. It mainly answers the following two main questions: 1. What are the risk factors for clinically relevant postoperative pancreatic fistula in different pancreatic surgeries? 2. What is the correlation between perioperative blood and interstitial fluid glucose level and clinically relevant postoperative pancreatic fistula in different pancreatic surgeries? Participants were not required to perform additional research work other than the usual postoperative follow-up within 30 days after surgery. No control group was set in this study, and no additional clinical intervention was performed.

NCT ID: NCT06289517 Not yet recruiting - Neoplasms Clinical Trials

PET Imaging of 68Ga-Her2-affibody in Tumors With High Her2 Expression

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

NCT ID: NCT06289452 Recruiting - Eye Diseases Clinical Trials

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis

Start date: March 8, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.

NCT ID: NCT06289166 Recruiting - Hemophilia Clinical Trials

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Start date: March 18, 2024
Phase: Phase 2
Study type: Interventional

This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.

NCT ID: NCT06289062 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, PFS and OS.

NCT ID: NCT06289036 Completed - Clinical trials for The Levels of Cerebral Perfusion and Collateral Circulation in Patients With Subacute Stroke

Prognosis in Subacute Ischemic Stroke Using Multimodal Imaging

Start date: February 1, 2021
Phase:
Study type: Observational

We enrolled patients with subacute IS, associated with moderate-to-severe stenosis of the unilateral cervical internal carotid artery, who underwent 4D ASL. Perfusion levels and collateral circulation were compared between groups with favorable prognosis (modified Rankin scale [mRS] ≤ 2) and poor prognosis (mRS > 2).

NCT ID: NCT06289023 Completed - Brain Metastases Clinical Trials

HA-WBRT-SIB for Brain Metastasis of Lung Cancer

Start date: January 1, 2016
Phase: Phase 2
Study type: Interventional

Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to 44 Gy-52 Gy in 18-20 fractions, five times a week. The optimal mean dose (Dmean) to the bilateral hippocampus should optimally be ≤ 8 Gy, with a mandatory maximum dose (Dmax) to the hippocampus not exceeding 10 Gy; the preferred Dmean to the hippocampus PRV should optimally be ≤ 9 Gy, while the mandatory Dmax to the hippocampus PRV should be ≤ 12 Gy. The HVLT-R immediate recall scores are obtained at baseline and 1, 3, and 6 months after treatment.

NCT ID: NCT06288997 Completed - Clinical trials for Methamphetamine-dependence

tACS Intervention for Methamphetamine Addiction

tACS for MUD
Start date: November 21, 2021
Phase: N/A
Study type: Interventional

A growing body of evidence suggests a wide range of brain areas are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial alternating current stimulation (tACS) over prefrontal cortex reduces craving for meth dependences. In this study, the investigators investigated whether a current level of 15mA with a patented frequency of 77.5Hz tACS intervention of prefrontal cortex cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.